Global Antisense And Rni Therapeutic Market: Market Size & Forecast 2026

Antisense and RNAi therapeutics represent a growing class of precision medicines designed to modulate gene expression at the RNA level. The global market reached roughly $7.38 billion in 2025 and is expected to grow to approximately $17.81 billion by 2030 at a 6.74% CAGR. This segment sits within the broader RNA therapeutics space, which is valued at over $20 billion and encompasses mRNA vaccines, siRNA drugs, and antisense oligonucleotides.

• •Market valued at approximately $7.38 billion in 2025, projected near $17.81 billion by 2030
• •Two primary technology platforms: RNA Interference (RNAi) and Antisense RNA oligonucleotides
• •Common routes of administration include intrathecal and intravenous delivery

The market is benefiting from increasing regulatory approvals of oligonucleotide-based drugs targeting rare genetic disorders, neuromuscular conditions, and ocular diseases. Advances in drug delivery technologies, including lipid nanoparticles and GalNAc conjugation, have significantly improved the ability of these therapies to reach target tissues effectively. Additionally, growing investment from pharmaceutical companies and expanding clinical-stage pipelines across neurology, oncology, and metabolic diseases are accelerating development activity worldwide.

• •Rising number of regulatory approvals for antisense and RNAi drugs, particularly in rare genetic and ocular indications
• •Delivery technology improvements such as lipid nanoparticles and ligand conjugates expanding treatable patient populations
• •Robust clinical pipeline spanning neurology, oncology, cardiovascular, and metabolic disease areas

The market is segmented by technology, RNA interference and antisense RNA, as well as by application areas including ocular and genetic disorders, and by route of administration such as intrathecal and intravenous. The antisense oligonucleotides sub-segment alone is projected to grow from roughly $3.3 billion in 2025 toward $6.1 billion by 2035. North America currently leads in market share, supported by strong regulatory pathways and advanced biopharmaceutical infrastructure, while Europe and Asia-Pacific are emerging as significant growth regions due to expanding clinical research networks.

• •Technology split: RNA interference (siRNA-based) and Antisense RNA (ASO-based) platforms
• •Antisense oligonucleotides sub-segment expected from approximately $3.3 billion (2025) to $6.1 billion (2035)
• •North America leads regional share, with Europe and Asia-Pacific showing expanding clinical and commercial activity

What are the recent trends and outlook?

The field is moving toward next-generation chemistries and delivery systems designed to extend dosing intervals, reduce toxicity, and broaden tissue targeting beyond the liver to the central nervous system and muscle. RNA editing technologies and gene-silencing approaches are emerging as complementary or replacement strategies to traditional small-molecule drugs. Long-term forecasts suggest sustained double-digit growth as more therapies advance through Phase III trials and achieve regulatory approval, with the global oligonucleotide therapeutics sector on track to exceed $45 billion in the broader RNA therapeutics landscape by the early 2030s.

• •Next-generation oligonucleotide chemistries and advanced delivery platforms targeting CNS and muscle tissues
• •Emerging RNA editing and gene-silencing technologies expanding therapeutic potential beyond current approved indications
• •Market on path toward sustained growth as clinical pipelines mature and regulatory approvals accumulate through 2030 and beyond